A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOM TO SALPINGO-OOPHOPECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]

Chung-Ang Univerisity Hospital0 个研究点目标入组 2,262 人开始时间: 待定最近更新: 2022年10月24日

试验速览

阶段: 未知
状态: 尚未招募
发起方
入组人数: 2,262

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional Study

入排标准

年龄范围: 35(Year) 至 50(Year)（—）
性别: Female

入选标准

•1. Women 35-50 years of age, inclusive
•2. Patients who have declined or elected to defer risk-reducing salpingo-oophorectomy (RRSO) after proper
•counselling to clearly explain the standard of care for BRCA1 mutation carriers (for the BLS with delayed
•oophorectomy arms) or patients who are undergoing RRSO (for the RRSO arm)
•3. At least one intact ovary and fallopian tube is in situ at the time of counseling and consent. Prior
•hysterectomy is allowed provided it did not include bilateral salpingectomy. Prior tubal ligation is allowed if
•one intact ovary and tube are present
•4. Positive Clinical Laboratory Improvement Act (CLIA)-approved test results for pathogenic or likely
•pathogenic germline BRCA1 mutation in the patient herself. Documentation of the result is required
•6. Premenopausal; defined as < 12 months of amenorrhea. However, for those patients with >= 12 months of
•amenorrhea who may be pre-menopausal or patients with a prior hysterectomy with at least one retained
•ovary/tube, levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and in the premenopausal
•range per local institutional standards will be acceptable. Concurrently planned hysterectomy with
•salpingectomy for the BS group or with BSO for the BSO group is permitted
•7. Transvaginal ultrasound (TVUS) and CA-125 within 180 days of registration
•8. The patient or a legally authorized representative must provide study-specific informed consent prior to
•study entry

排除标准

•1. Women with a history of any prior cancer who have received chemotherapy within the past 12 months,
•hormonal therapy in the past 90 days, or radiotherapy to abdomen or pelvis at any prior time
•2. Prior history of ovarian cancer, including low malignant potential neoplasms (LMP), primary peritoneal
•carcinoma, or fallopian tube carcinoma
•3. Patients medically unfit for the planned surgical procedure
•4. Patients with abnormal screening tests (TVUS, CA-125) suspicious for occult or gross pelvic malignancy or
•neoplasm within the past 180 days
•- An abnormal TVUS is defined as morphologic or structural variations suspicious for ovarian malignancy or
•complex cystic lesions (simple cysts < 5 cm in maximal diameter are not exclusionary)
•- An abnormal CA-125 is defined as a level > 50 U/ml in this study population of premenopausal women if
•they are not current users of oral contraceptives; an abnormal CA-125 is defined as a level > 40 U/ml for
•premenopausal women who are current users of oral contraceptives
•5. Women who are currently pregnant or plan to become pregnant in the future

研究者

发起方

Chung-Ang Univerisity Hospital

相似试验

尚未招募

不适用

CLINICAL TRIAL TO COMPARE AND EVALUATE THE EFFECTIVENESS OF LOW INTENSITY PULSED ULTRASOUND (LIPUS) AND LOW-LEVEL LASER THERAPY (LLLT) IN TREATING SKELETAL CLASS II CASES WITH FUNCTIONAL APPLIANCES.

CTRI/2021/12/038869Sri Hasanamba dental College and Hospital

尚未招募

2 期

ROLE OF TRYUSHANADYA LAUHA AND LEKHANIYA MAHAKASHAYA IN STHAULAY (OBESITY) TO REDUCE WEIGHT.

CTRI/2022/03/040968ATIONAL INSTITUTE OF AYURVEDA DEEMED TO BE UNIVERSITY JAIPUR

尚未招募

1 期

To Compare the efficacy of Dhatri Loha with tablet Ferrous Sulphate in Pandu (Anaemia)

CTRI/2020/03/024120PDEAs college of Ayurved and Research Centre Nigdi Pune

已完成

3 期

EDARAVONE IN ACUTE ISCHEMIC STROKE

CTRI/2009/091/000309ONE52

进行中（未招募）

不适用

Comparing two doses of botulinum toxin A in the tretatment of urinary symptomsidiophatic overactive bladderC12.777.829.866

RBR-25k53mFaculdade de Ciências Médicas da Santa Casa de São Paulo